mRNA Vaccines Effective for Preventing Symptomatic COVID-19 – MPR
Vaccine effectiveness 82 and 94 percent for single dose, two doses among U.S. health care personnel at 33 sites across 25 U.S. states.
Related Articles
Meningococcal ABCWY Vaccine Candidate Under FDA Review
A regulatory decision is expected on February 14, 2025.
Entyvio for Subcutaneous Use Approved for Maintenance in Crohn Disease
The approval was based on data from the phase 3 VISIBLE 2 trial.
Tirzepatide Products Continue to Be in Short Supply
The shortage is expected to continue at least through the second quarter of 2024.
Sudan Ebola Virus Vaccine Candidate Gets Orphan Drug Status
SuVax is a subunit protein vaccine of recombinantly expressed Sudan ebolavirus glycoprotein.
US Medical Drug Shortages Reach Record High
A record high of 323 different meds were in short supply during the first quarter of 2024,
Tirzepatide Improves Sleep Apnea Symptoms in Obese Patients With OSA
The double-blind, phase 3 study included 2 groups of patients, those who were not on positive airway pressure therapy and those who were.
FDA: Adverse Events Linked to Counterfeit Versions of Botox
All of the affected individuals were females who received the injections in non-health care settings by untrained individuals who purchased the product from unlicensed sources.
FDA Grants Orphan Drug Status to Anti-Properdin Antibody for PNH
NM5072 is a potential first-in-class monoclonal antibody that selectively blocks properdin, a protein of the complement alternative pathway.
On-Body Infusor System for Repatha to Be Discontinued Soon
The Repatha Pushtronix System will be discontinued as of June 30, 2024.
Mpox At-Home Collection Kit Gets FDA’s Emergency Use Authorization
The kit includes a lesion swab, collection tube, and a return package to an authorized laboratory for analysis.